Hepatitis C Virus Infection, Response to Therapy of Clinical Trial
Official title:
Effects of Personalized Physical Activity and Psycho-Education Program on Patients With Chronic Hepatitis C Infection
This 4-year project will be guided by a biobehavioral model for the study of exercise
interventions in two phases with the purposes to :
1. explore the patients' physical activity preferences and develop doable activity lists
during treatment period
2. examine the changes of health-related physical fitness component over interferon
treatment
3. develop the Personalized Physical Activity and Psych-Education (PPAPE) Program and test
its effects on decreasing fatigue, physical and psychological distress, and improving
their health-related physical fitness and quality of life in patients with chronic
hepatitis C receiving Interferon with Ribavirin Combination Therapy
4. evaluate the outcome of the PPAPE program on increasing adherence to therapy, the
sustained virological response (SVR) in 24 weeks after the end of treatment, and the
time-consuming for education program during intervention.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | June 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Patients with Chronic Hepatitis C Infection Receiving Interferon Therapy - Aged above 18 Exclusion Criteria: |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital | National Health Research Institutes, Taiwan |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effects of Activity and Education Program on Patients with Chronic Hepatitis C Infection | Phase I of this project, the first and second year, the measurement time will be collected on the baseline (before treatment, T0), the 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) during treatment. | 4-year project | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04596475 -
Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor
|
Phase 1/Phase 2 | |
Recruiting |
NCT05361603 -
Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures
|
||
Recruiting |
NCT05376943 -
Possible Differences in HCC Course Depending on DAA Treatment
|
||
Recruiting |
NCT04251572 -
HCV Reinfection After DAA Therapy in PWID in Belgium
|
N/A | |
Completed |
NCT03369327 -
Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus
|
Phase 3 | |
Recruiting |
NCT04768517 -
HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
|
||
Recruiting |
NCT04732832 -
HCV Reinfection in HD Patients Achieving SVR
|
||
Withdrawn |
NCT03381859 -
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4
|
Phase 4 | |
Recruiting |
NCT04677153 -
Rapid HCV Treatment Access for Persons Who Use Drugs
|
N/A | |
Completed |
NCT03453346 -
Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C
|
N/A | |
Completed |
NCT02402218 -
CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS
|
N/A | |
Completed |
NCT01473056 -
Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects
|
Phase 1 | |
Completed |
NCT03250910 -
Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients
|
Phase 4 | |
Enrolling by invitation |
NCT03343444 -
Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents
|
Phase 3 |